Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal folic acid dose with methotrexate in rheumatic diseases
jRCT1061230085Completed
- Sponsor
- Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of folic acid in rheumatoid arthritis (RA) and rheumatism (2 arms), sponsored by Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital. Primary endpoint: Incidence of liver damage at 12 weeks. Started Jul 2024; status: completed.
02
Drugs
folic acid
03
Conditions
rheumatoid arthritis (RA)rheumatism
Beyond the preview
Go deeper on jRCT1061230085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061230085.